Mass drug administration to reduce malaria incidence in a low-to-moderate endemic setting: short-term impact results from a cluster randomised controlled trial in Senegal
Elhadji Ba Konko Ciré,Michelle E. Roh,Abdoulaye Diallo,Tidiane Gadiaga,Amadou Seck,Sylla Thiam,Seynabou Gaye,Ibrahima Diallo,Aminata Colle Lo,Elhadji Diouf,Omar Gallo Ba,Alioune Badara Gueye,Ari Fogelson,Xue Wu,Paul JM Milligan,Tabitha Kibuka,Moustapha Hama,Erin Eckert,Julie Thwing,Adam Bennett,Roly Gosling,Jimee Hwang,Doudou Sene,Fatou Ba,Bayal Cissé,Katharine Sturm-Ramirez,Michelle S. Hsiang,Jean Louis Ndiaye
DOI: https://doi.org/10.1101/2024.07.17.24310593
2024-07-18
Abstract:Background
In Africa, the scale-up of malaria control interventions, including seasonal malaria chemoprevention (SMC), has dramatically reduced malaria burden, but progress toward malaria elimination has stalled. We evaluated mass drug administration (MDA) as a strategy to accelerate reductions in malaria incidence in Senegal.
Methods
We conducted an open-label, cluster-randomised controlled trial in a low-to-moderate transmission setting of Tambacounda, Senegal. Eligible villages had a population size between 200-800. All villages received pyrethroid-piperonyl butoxide bednets and proactive community case management of malaria at baseline. Sixty villages were randomised 1:1 to either three cycles of MDA with dihydroartemisinin-piperaquine+single-low dose primaquine administered to individuals aged ≥3 months, six-weeks apart starting the third week of June (intervention), or standard-of-care, which included three monthly cycles of SMC with sulfadoxine-pyrimethamine+amodiaquine administered to children aged 3-120 months starting end of July (control). MDA and SMC were delivered door-to-door. The primary outcome was clinical malaria incidence in all ages assessed during the peak transmission season (July-December), the year after intervention. Here, we report safety, coverage, and impact outcomes during the intervention year. The trial is registered at ClinicalTrials.Gov ( ).
Findings
Between June 21, 2021 and October 3, 2021, 6505, 7125, and 7250 participants were administered MDA and 3202, 3174, and 3146 participants were administered SMC across cycles. Coverage of ≥1 dose of MDA drugs was 79%, 82%, and 83% across cycles. During the transmission season of the intervention year, MDA was associated with a 55% [95% CI: 28%-72%] lower incidence of malaria compared to control (MDA: 93 cases/1000 population; control: 173 cases/1000 population). No serious adverse events were reported in either arm.
Interpretation
In low-to-moderate malaria transmission settings with scaled-up malaria control interventions, MDA with dihydroartemisinin-piperaquine+single-low dose primaquine is effective and well-tolerated for reducing malaria incidence. Further analyses will focus on the sustainability of this reduction.
Funding
United States Presidents Malaria Initiative